WELWYN GARDEN CITY, England and BOSTON, January 8, 2014 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery and development company, notes that its President, Dan Grau, will moderate a panel discussion entitled "Global Entrepreneurs: Biotech Building Beyond Borders" (1:30-2:00pm Eastern time on 11 January) at the Boston Biotech East/West CEO Conference, which takes place at the Four Seasons Hotel, San Francisco, CA, USA on 11-12 January.
Mr Grau, Malcolm Weir (CEO), Fiona Marshall (CSO) and Barry Kenny (CBO) will attend the JPMorgan Healthcare conference, also in San Francisco, on 13-16 January.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our proprietary structure-based drug design technology platform, we have built an exciting pipeline of novel drug candidates with the potential to transform the treatment of serious diseases, including Alzheimer's disease, ADHD, diabetes, schizophrenia, and migraine. Our pharmaceutical partners include Cubist, MorphoSys, Takeda, AstraZeneca and MedImmune, and we are backed by Clarus Ventures, MVM Life Science Partners, Novartis Venture Fund, the Stanley Family Foundation and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com
HEPTARES is a registered trademark in the EU, Switzerland, US and Japan;
StaR is a registered trademark in the EU and Japan.
SOURCE Heptares Therapeutics